Evaluation of a New Topical Treatment for the Control of Cutaneous Leishmaniasis.

Details

Serval ID
serval:BIB_4B19C6BD731C
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Evaluation of a New Topical Treatment for the Control of Cutaneous Leishmaniasis.
Journal
Microorganisms
Author(s)
Martínez-Salazar B., Carregaro Pereira V., Hauyon-La-Torre Y., Khamesipour A., Tacchini-Cottier F.
ISSN
2076-2607 (Print)
ISSN-L
2076-2607
Publication state
Published
Issued date
17/11/2020
Peer-reviewed
Oui
Volume
8
Number
11
Pages
1803
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
Leishmania major (L. major) causes cutaneous leishmaniasis in the Old World. The infection mostly induces a localized lesion restricted to the sand fly bite. The costs and the side effects of current treatments render imperative the development of new therapies that are affordable and easy to administrate. Topical treatment would be the ideal option for the treatment of cutaneous leishmaniasis. MF29 is a 3-haloacetamidobenzoate that was shown in vitro to inhibit tubulin assembly in Leishmania. Here, we tested a topical cream formulated with MF29. BALB/c mice were infected in the ear dermis with L. major metacyclic promastigotes and once the lesion appeared, mice were treated with different concentrations of MF29 and compared to the control group treated with the cream used as the vehicle. We observed that topical application of MF29 reduced the progression of the infection while control groups developed an unhealing lesion that became necrotic. The treatment decreased the type 2 immune response. Comparison with SinaAmphoLeish, another topical treatment, revealed that MF29 treatment once a day was sufficient to control lesion development, while application SinaAmphoLeish needed applications twice daily. Collectively, our data suggest that MF-29 topical application could be a promising topical treatment for cutaneous leishmaniasis.
Keywords
L. major, Leishmania, MF-29, anti-leishmanial drug, topical treatment
Pubmed
Web of science
Open Access
Yes
Create date
28/11/2020 10:57
Last modification date
26/01/2022 7:36
Usage data